According to filings with the U.S. Securities and Exchange Commission, Wavegate is raising $10,000,000.00 in new funding. Sources indicate that as part of senior management Executive, Robert Ehlers played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Wavegate
Wavegate Corporation is a medical technology company engaged in development of internally-generated intellectual property (IP) pertaining to neuromodulation. Our patented StimuLux (TM) technology is uniquely poised to enhance the pain-relief and minimize side-effects from spinal cord stimulation (SCS) used for the treatment of chronic pain. Approximately 68,000 patients per year in the United States receive spinal cord stimulators for the treatment of chronic pain which is refractory to medical and/or surgical management. Spinal Cord Stimulators apply electrical signals to the spinal cord via an electrode array implanted within the spine. These electrical signals interfere with transmission of pain signals to the brain, hence decreasing the severity of the perceived pain. Because the spinal cord position shifts relative to the electrode array as a patient moves or changes posture, a fixed stimulation amplitude may result in noxious overstimulation or loss of efficacy through understimulation. Thus, optimal pain relief is achieved through real-time modulation of the electrical stimulation in response to spinal cord motion, a process known as adaptive neuromodulation. StimuLux (TM) optical sensing technology provides real-time, efficient, direct measurement of spinal cord position relative to the sensor array, allowing effective adaptive neuromodulation in response to real life activities.

To learn more about Wavegate, visit http://wavegate.us/

Contact:
Robert Ehlers, Executive
337-794-6390

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.